Concepedia

Haley Laken

HL

6

Publications

231

Citations

6

H-Index

2014

Active since

Affiliations

Third Dimension Technologies (United States)(Current)

Haley Laken is an author at Third Dimension Technologies (United States) specializing in medicine, pathology, and pharmacology.

Top concepts

Publications per year

2014–2022

6

Publications

6

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan et al. · Clinical Cancer Research · 2022 · 95 citations · Full text

Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131

Lex Van der Ploeg, Haley Laken, Shubh D. Sharma et al. · Life Sciences · 2014 · 53 citations

, , +9

Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody

A. Murtaza, Haley Laken, Jean da Silva Correia et al. · European Journal of Cancer · 2016 · 33 citations

, , +8

Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody

Haley Laken, Marilyn R. Kehry, Patricia McNeeley et al. · European Journal of Cancer · 2016 · 23 citations

, , +9

Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.

Glen J. Weiss, Jasgit C. Sachdev, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2014 · 14 citations

, , +18

Rows per page

1–5 of 6